Posted by Michael Wonder on 16 Aug 2022
Chugai obtains regulatory approval for osteoporosis treatment Edirol
15 August 2022 - Chugai Pharmaceutical and Towa Pharmaceutical announced that Chugai obtained regulatory approval from the MHLW for an osteoporosis treatment Edirol (eldecalcitol) 0.5 mcg/0.75 mcg tablets.
Edirol is an active vitamin D3 derivative created based on Chugai’s long-standing vitamin D research.
